argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Real-time Euronext Bruxelles Other stock markets 03:50:59 2024-04-23 am EDT			5-day change	1st Jan Change
341.5 ^EUR	+1.31%		-2.26%	-0.58%

Apr. 17	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 16	Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	CI

Argenx : to Report Full Year 2020 Financial Results and Fourth Quarter Business Update on March 4, 2021

February 25, 2021 at 01:00 am EST

February 25, 2021

Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on March 4, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its full year 2020 financial results and provide a fourth quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for one year following the call.

Dial-in numbers:
Please dial in 15 minutes prior to the live call.

Belgium                               0800 389 13
France                                  0805 102 319
Netherlands                       0800 949 4506
United Kingdom               0800 279 9489
United States                   1 844 808 7140
International                    1 412 902 0128

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, and Japan. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.

For further information, please contact:

Media:
Kelsey Kirk
KKirk@argenx.com

Investors:
Beth DelGiacco
bdelgiacco@argenx.com

Joke Comijn (EU)
jcomijn@argenx.com

Source: argenx SE

2021 GlobeNewswire, Inc., source Press Releases

Latest news about argenx SE

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
Argenx SE Announces Data from its Phase 3 ADHERE Trial Evaluating VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy	Apr. 16	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading	Apr. 04	MT
Argenx Se Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease	Mar. 27	CI
Scotiabank Raises Price Target on Argenx SE to $408 From $402, Maintains Sector Perform Rating	Mar. 26	MT
Argenx Gets Japanese Regulator's Approval for Intravenous Use of Vyvgart in Primary Immune Thrombocytopenia	Mar. 26	MT
Argenx SE Announces Approval of Vyvgart (Efgartigimod Alfa) in Japan for Adults with Primary Immune Thrombocytopenia	Mar. 26	CI
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	Mar. 21	MT
US Futures, European Stocks Rise After Fed Maintains Outlook	Mar. 21	DJ
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
Truist Securities Raises Price Target on Argenx to $440 From $370, Maintains Buy Rating	Mar. 05	MT
JMP Securities Adjusts Argenx's Price Target to $471 From $462, Keeps Market Outperform Rating	Mar. 01	MT
Baird Cuts Price Target on Argenx to $490 From $505, Maintains Outperform Rating	Mar. 01	MT
Global markets live: HP, Moncler, Snowflake, Salesforce, Duolingo...	Feb. 29
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Feb. 29	MT
Sector Update: Health Care Stocks Advance Premarket Thursday	Feb. 29	MT
Sector Update: Health Care	Feb. 29	MT
Transcript : Argenx SE, Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Argenx Q4 Loss Widens, Revenue Increases -- Shares Down Pre-Bell	Feb. 29	MT
Argenx SE Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	Feb. 20	MT
Argenx Says FDA Accepted for Priority Review Supplemental BLA for Autoimmune Disease Drug Vyvgart Hytrulo	Feb. 20	MT
US FDA Accepts for Priority Review Argenx's Biologics License Application for Vyvgart Hytrulo	Feb. 20	MT
Argenx SE Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy	Feb. 20	CI
Wolfe Research Starts Argenx With Peer Perform Rating	Feb. 15	MT

Chart argenx SE

Duration

Period

More charts

Company Profile

argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Annual General Meeting

Related indices

STOXX EUROPE 600 (EUR) , BEL-20

More about the company

Income Statement Evolution

More financial data

Ratings for argenx SE

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

337.1 EUR

Average target price

439.4 EUR

Spread / Average Target

+30.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARGENX SE	-0.58%	21.31B
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.24%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B
ASCENDIS PHARMA A/S	+12.82%	8.12B

Bio Therapeutic Drugs